ENROUTE Transcarotid Neuroprotection System
Commercial- Indications
- Carotid artery disease
Company intelligence / Profile preview
The TCAR system developed by Silk Road Medical received FDA approval in 2015 and has demonstrated reduced risk of stroke and complications compared to traditional open surgery for carotid revascularization. It remains the only commercially available device for this minimally invasive procedure. Clinical studies support its safety and efficacy for patients at risk of stroke due to carotid artery disease.
4 more assets in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Silk Road Medical.